Side-by-side comparison of AI visibility scores, market position, and capabilities
AI-powered CDI, coding, and utilization management platform improving revenue accuracy for health systems; raised $80M+. Austin TX;
Iodine Software is an AI health IT company that specializes in clinical documentation integrity (CDI), medical coding, and utilization management for inpatient and outpatient care settings. Founded in 2010 and headquartered in Austin, Texas, Iodine has raised more than $80 million and serves dozens of health systems representing hundreds of hospitals across the United States. The company's flagship product, Artifact, uses machine learning trained on millions of clinical encounters to predict documentation gaps, suggest appropriate diagnosis codes, and prioritize physician query opportunities in real time as patients receive care.\n\nIodine's approach is distinguished by the depth of its AI models, which are trained on a proprietary dataset of clinical notes, lab values, and billing outcomes. This allows Artifact to identify clinically significant conditions that may be present but undocumented — such as malnutrition, sepsis, or respiratory failure — and surface targeted queries to CDI specialists and physicians before documentation windows close. The platform integrates with major inpatient EHRs including Epic and Oracle Cerner, embedding intelligence directly into CDI and coding workflows.\n\nBeyond CDI, Iodine has expanded into utilization management and care progression analytics, helping hospitals identify patients who may be inappropriately placed in observation status versus inpatient, reduce length of stay outliers, and defend against payer audits. The company competes with 3M Health Information Management, Optum, and a growing number of AI-native CDI vendors, and has established itself as a trusted partner for health systems seeking to improve documentation accuracy and revenue cycle integrity.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.